In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli

Mariana Albano, Wim Alexander Fleischmann, Kerryl E. Greenwood-Quaintance, Robin Patel

Research output: Contribution to journalArticlepeer-review


Background: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. Methods: Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values. Results: The MIC values required to inhibit 50% and 90% of isolates (MIC50 and MIC90, respectively) were 16 and >128 μg/ml, respectively. Conclusions: Arbekacin showed similar MIC50 values to amikacin and gentamicin, a lower MIC50 value than tobramycin, and a higher MIC50 value than plazomicin.

Original languageEnglish (US)
Pages (from-to)1118-1121
Number of pages4
JournalJournal of Microbiology, Immunology and Infection
Issue number6
StatePublished - Dec 2021


  • Arbekacin
  • Enterobacterales
  • Multidrug-resistant gram-negative bacilli

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli'. Together they form a unique fingerprint.

Cite this